Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/WNL.0000000000009156 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thrombolysis after dabigatran reversal: A nation-wide Italian multicentre study, systematic review and meta-analysis.
Eur Stroke J
March 2023
Neurologia e Stroke Unit, Ospedale di Gubbio e Città di Castello, USL Umbria 1, Perugia, Italy.
Introduction: Recent anticoagulant intake represents a contraindication for thrombolysis in acute ischemic stroke. Idarucizumab reverses the anticoagulant effect of dabigatran, potentially allowing for thrombolysis. This nation-wide observational cohort study, systematic review, and meta-analysis evaluated the efficacy and safety of thrombolysis preceded by dabigatran-reversal in people with acute ischemic stroke.
View Article and Find Full Text PDF[First case of thrombolysis with non-immunogenic staphylokinase in a patient with ischemic stroke receiving dabigatran etexilate followed by thrombectomy].
Zh Nevrol Psikhiatr Im S S Korsakova
June 2022
Sklifosovsky Clinical and Research Institute for Emergency Medicine, Moscow, Russia.
Currently, five oral anticoagulants have been shown to be effective in preventing recurrent ischemic stroke and/or systemic embolism in patients with non-valvular atrial fibrillation. However, 1.1-2.
View Article and Find Full Text PDFRevascularization outcomes following acute ischemic stroke in patients taking direct oral anticoagulants: a single hospital cohort study.
J Thromb Thrombolysis
January 2021
Department of Vascular Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Successful revascularization therapy is of paramount importance in patients suffering acute ischemic stroke (AIS). However, there is currently only limited evidence on revascularization outcomes for patients suffering AIS while treated with direct oral anticoagulants (DOACs). The aim of our study was to determine the efficacy and safety of intravenous thrombolysis (IVT) and mechanical reperfusion (MeR) in AIS patients taking DOACs, and compare them to randomized clinical trials (RCTs), which included patients without DOAC treatment.
View Article and Find Full Text PDFStroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort.
Neurology
May 2020
From the Department of Neurology (P.A.B.), Auckland City Hospital; Department of Neurology (T.Y.W.), Christchurch Hospital; Department of Neurology (A.R.), Wellington Regional Hospital; and Department of Medicine (A.R.), University of Otago, Wellington, New Zealand.
Objective: To assess the frequency and utilization trends of dabigatran reversal with idarucizumab and compare associated complications, outcomes, and door-to-needle times to those of patients not exposed to idarucizumab in a nationwide cohort of thrombolyzed patients over a 24-month period.
Methods: This is an observational cohort study of all New Zealand patients with stroke treated with stroke reperfusion entered into a mandatory online national registry. Each hospital records data including patient demographics, treatment delays, complications, 7-day outcomes, and idarucizumab use.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!